Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × NSCLC × tislelizumab × Clear all

Phase

Status

Recruiting 1 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 8 Esophageal Squamous Cell Carcinoma 6 Carcinoma, Non-Small-Cell Lung 6 Stomach Neoplasms 4 Neoplasm Metastasis 4 Head and Neck Neoplasms 4 Recurrence 3 Lung Neoplasms 3 Colorectal Neoplasms 3 Advanced Solid Tumors 3 Advanced Solid Tumor 3 Squamous Cell Carcinoma of Head and Neck 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Solid Tumors 1 Small Cell Lung Carcinoma 1 Pancreatic Neoplasms 1 Pancreatic Ductal Adenocarcinoma 1 Ovarian Neoplasms 1 Neoplasms 1 Nasopharyngeal Neoplasms 1 NSCLC 1 Multiple Pulmonary Nodules 1 Mid-low Rectal Cancer 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, T-Cell 1 Lymphoma, Mantle-Cell 1

Interventions

osimertinib 2 Vinorelbine 2 HMPL-013 2 Gefitinib 2 tislelizumab 1 sulindac sulfone 1 rezivertinib 1 anlotinib 1 Radiotherapy 1 Platinum 1 Pemetrexed 1 Paclitaxel 1 Liquid Biopsy 1 Gemcitabine 1 Cisplatin 1 Cetuximab 1 Carboplatin 1 CP protocol 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05058560 2025-03-13

Tislelizumab in Addition to BACE in Patients with NSCLC

The First Affiliated Hospital of Zhengzhou University

Phase 2 Completed

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡